Company Monitoring Page for Biogen

latest headlines for company on cafepharma

7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
Tags:
FDA, adagrasib, donanemab, faricimab, lecanemab, tezepelumab, tirzepatide, vutrisiran, Eli Lilly, Mirati Therapeutics, Roche, Chugai, Eisai, Biogen, AstraZeneca, Amgen, Alnylam
JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor
Fierce Biotech
Wed, 01/12/22 - 11:12 am
Tags:
JPMHC 2022, BeiGene, Ionis Pharmaceuticals, Roche, devices, AstraZeneca, Biogen
For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst
Fierce Pharma
Wed, 01/12/22 - 11:01 am
Tags:
CMS, Biogen, Aduhelm, Medicare, clinical trials, Alzheimer's disease
Medicare proposes to limit coverage of Biogen Alzheimer's drug
BioPharma Dive
Tue, 01/11/22 - 10:22 pm
Tags:
Biogen, Aduhelm, CMS, Medicare
5 questions facing the FDA in 2022
BioPharma Dive
Tue, 01/11/22 - 10:20 pm
Tags:
FDA, regulatory, Robert Califf, Biogen, Aduhelm
JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies
BioPharma Dive
Mon, 01/10/22 - 11:52 pm
Tags:
JPMHC 2022, Pfizer, MRNA, Biogen, Aduhelm, cell therapy
Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?
Fierce Pharma
Thu, 01/6/22 - 12:59 pm
Tags:
Biogen, Aduhelm, Medicare, CMS, Alzheimer's disease
Biogen brings in a successor to Spinraza
BioPharma Dive
Tue, 01/4/22 - 10:49 pm
Tags:
Biogen, Ionis Pharmaceuticals, Spinraza, BIIB115, antisense, spinal muscular atrophy
Biogen and Eisai move forward with investigational Alzheimer's therapy
Biopharma Reporter
Mon, 01/3/22 - 10:45 pm
Tags:
Biogen, Eisai, lecanemab, Alzheimer's disease, fast track, FDA
Biopharma developments over the Christmas period
EP Vantage
Mon, 01/3/22 - 10:26 am
Tags:
Alnylam Pharmaceuticals, Bio-Thera Solutions, BioArctic, Biogen, BridgeBio Pharma, Daiichi Sankyo, Eisai, JNJ, Madrigal Pharmaceuticals, Merck, Sutro BioPharma, Tasly Pharmaceutical Group
To buy or not to buy? Samsung unit denies report about Biogen talks
Fierce Pharma
Thu, 12/30/21 - 11:09 am
Tags:
Biogen, Samsung BioLogics, M&A
Biogen surges on potential buyout deal from South Korea's Samsung Group
Seeking Alpha
Wed, 12/29/21 - 02:34 pm
Tags:
Biogen, M&A, Sansung Group
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
Fierce Biotech
Tue, 12/28/21 - 10:55 am
Tags:
Biogen, Eisai, lecanemab, FDA, Aduhelm, fast track, Alzheimer's disease
2022 forecast: How marketers must learn from Biogen's marketing struggles with Aduhelm
Fierce Pharma
Mon, 12/27/21 - 11:10 am
Tags:
Biogen, Aduhelm, pharma marketing, Alzheimer's disease, Roche, Eli Lilly
What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?
Forbes
Sun, 12/26/21 - 11:16 pm
Tags:
Biogen, Aduhelm, drug pricing, Alzheimer's disease
2022 forecast: Will biopharma's offices ever go back to 'normal'? Sanofi, Novartis and more chime in
Fierce Pharma
Wed, 12/22/21 - 11:37 pm
Tags:
COVID-19, pandemic, remote work, Sanofi, Biogen, Pfizer, Novartis
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
Fierce Pharma
Wed, 12/22/21 - 11:06 am
Tags:
Biogen, Eisai, Aduhelm, Japan, Alzheimer's disease
Alzheimer's experts call on FDA to pull Biogen's Aduhelm
Endpoints
Tue, 12/21/21 - 10:31 am
Tags:
Biogen, Aduhelm, FDA, Alzheimer's disease
Biogen halves Aduhelm's price and plots cost cuts as Medicare decision on controversial Alzheimer's drug nears
Fierce Pharma
Mon, 12/20/21 - 11:11 am
Tags:
Biogen, Aduhelm, Alzheimer's disease, drug pricing, layoffs
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
Pharmaforum
Fri, 12/17/21 - 11:11 am
Tags:
Biogen, Aduhelm, Europe, Alzheimer's disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.